

# **The CU Technology Transfer Performance Metrics with a Recent Historical Perspective**

**July 2008**

# CU Technology Transfer Over the Past Eight Years

Fiscal Year	00-1	01-2	02-3	03-4	04-5	05-6	06-7	<b>07-8</b>
Invention disclosures	79	121	124	147	177	198	254	<b>235</b>
U.S. patent apps filed	46	59	82	100	139	125	156	<b>185</b>
Total options/licenses	13	26	34	47	59	57	75	<b>58</b>
Exclusive opt/licenses	9	16	13	19	22	36	38	<b>45</b>
Revenue in \$MM*	2.2	2.1	3.1	5.8	21.7	20.6	22.7	<b>6.1</b>
Start-up companies	3	3	6	9	9	10	10	<b>11</b>

\*does not include revenue derived from legal settlements which in FY2003-4 amounted to \$28.1M, in FY2004-5 \$6.7M, in FY 2005-6 \$.7M, and in FY2006-07 \$1.3M.

# Last Five Years of Technology Transfer Transactions by Type

Fiscal Year	03-4	04-5	05-6	06-7	07-8
Total options/licenses	47	59	57	75	<b>58</b>
Exclusive opt/licenses	19	22	36	38	<b>45</b>
Non-exclusive licenses	22	37	21	37	<b>13</b>
Options (included in exclusive counts)	7	11	19	16	<b>20</b>

# Companies Created Based on CU Intellectual Property, FY 2007-08

❖ 2C Tech Corp.	Method for treating vision loss and blindness due to retinal damage
3QMatrix, Inc.	Degradable thiolene hydrogel for wound care and drug delivery
BioAMPS International, LLC	Antimicrobial compounds for treatment of lethal infectious diseases
HepQuant, LLC	Non-invasive method to quantitatively measure liver function for diagnosing liver disease and monitoring therapeutic efficacy.
Kennebec Partners, LLC	Novel soft matter testing technology for tissue regeneration applications
Peak Aging, Inc.	Neurological assessment tools and cognitive wellness systems for elderly adults
Precision Biopsy, LLC	Optical biopsy needle for improved diagnosis of prostate and other cancers
Sierra Neuropharmaceuticals	Drug reformulations and system for delivering antipsychotic drugs directly to the brain
Taiga Biotechnologies, Inc.	Stem cell based method for treatment of immune deficiency, cancer and leukemia
TraumTech, Inc.	Web-based self-empowerment modules for individuals recovering from trauma
V-Clip Pharmaceuticals	Immune-based therapeutics for treatment of viral and autoimmune diseases

❖ indicates a CU Proof of Concept investment recipient

## **Summary and Implications: FY 2007-08 compared to previous years**

- Invention disclosure activity remains robust, although slightly down from the previous year.
- Our exclusive license and option activity was slightly higher than last year. These are the “coins of our realm,” since they convey assets to companies that will be further developed and commercialization; typically yielding significant social and economic impact.

# **Summary and Implications:**

## **The last five years of tech transfer**

- CU's technology transfer operation has become a mature, consistent flow of intellectual property (IP) and transactions.
- During this period CU intellectual property has generated over \$113.7M in revenue, which been distributed to inventors, their labs and departments, and TTO.
- TTO is investing back into CU IP through various programs, and CU technology transfer has become a growing economic engine for Colorado.

# **Summary and Implications: Looking ahead**

- In July 2008 HB-08 1001 became law. This legislation provides \$26.5M in bioscience funding over the next five years, 30% of which will be directed at proof-of-concept research for university technologies. Matching money for the POC will be available from the Boettcher Foundation and CU. Additionally, 30% of the funds will be directed as matching money to university licensee companies.
- As these high-potential technologies enter our pipeline, we anticipate continued increases in both licensing and startup companies.